Table 1.

Breast cancer outcomes in clinical trials of CETP inhibitors

Study name	Description	Reported outcomes related to breast cancer
ILLUMINATE47	Torcetrapib, N = 15,067 high cardiovascular risk, 1–2-year follow-up, 1,679 women in active and 1,673 women in comparator group	No specific reporting on breast cancer. There was 1 cancer death in the torcetrapib group and 0 in the comparator group. Serious adverse events affecting the “reproductive system or breast” occurred in 27 active and 18 control persons.
dal-OUTCOMES48	Dalcetrapib, N = 15,871 post-acute coronary syndrome, 31-month follow-up, 1,573 women in active and 1,497 women in comparator group	No specific reporting on breast cancer. Malignant or unspecific tumours occurred in 270 persons (48 fatal) in the active group and in 286 persons (47 deaths) in the comparator group.
ACCELERATE49	Evacetrapib, N = 12,092 high vascular risk, 26-month follow-up, 1,390 women in active and 1,394 women in comparator group	No reporting of breast cancer.
REVEAL15	Anacetrapib, N = 30,449 high vascular risk, 4.1-year follow-up, 2,459 women in active and 2,456 women in comparator group	Breast cancer occurred in 24 persons in the active, and 27 persons in the comparator group.